Hepatitis B Vaccine Study Approved for Newborns
The University of Southern Denmark plans to study vaccine timing in 14,000 newborns in Guinea-Bissau.
Updated on Oct. 11, 2026 in Babies
Live Poll
Should researchers use local standards of care for clinical trials in low-income countries?
The University of Southern Denmark has approved a CDC-funded clinical trial involving 14,000 newborns in Guinea-Bissau. The study aims to compare the effects of administering the hepatitis B vaccine at birth versus the current national schedule, which begins at 6 weeks.
Why it matters
The trial addresses a critical health gap in a country where approximately 12% of adults live with chronic hepatitis B. Testing the impact of a birth dose could inform future vaccination policies as the nation prepares to introduce a formal birth dose mandate by 2028.
The study aims to enroll 14,000 newborns with $1.6 million in CDC funding to evaluate vaccination timing. Researchers note that 90% of infants infected with hepatitis B at birth develop chronic infection, which carries a high risk of liver cancer.
The players
Peter Aaby
He is a lead researcher at the Bandim Health Project who is directing the clinical trial in Guinea-Bissau.
Christine Stabell Benn
She is a lead researcher at the Bandim Health Project collaborating on the vaccination study.
Bandim Health Project
This research institution operates in Guinea-Bissau and focuses on improving health outcomes through public health initiatives.
Centers for Disease Control and Prevention
This United States federal agency provided $1.6 million in funding to support the clinical trial.
University of Southern Denmark
This academic institution based in Denmark has approved the research study protocol for newborn vaccination.
The details
The research, led by Peter Aaby and Christine Stabell Benn of the Bandim Health Project, will randomize infants to receive the hepatitis B vaccine at birth or wait until 6 weeks of age. Protocols also include administering tuberculosis and polio vaccines alongside the birth dose for those in the experimental group.
Timeline
The WHO issued a statement on the planned trial in February 2026.
A revised study protocol received approval from the Guinea-Bissau ethics committee in summer 2026.
The University of Southern Denmark officially approved the research study in October 2026.
Guinea-Bissau plans to introduce a national hepatitis B birth dose policy by 2028.
Culture Shift
The clinical trial reflects a growing global shift toward early pediatric immunization to combat endemic viral risks in developing nations. By testing birth-dose protocols, researchers are bridging the gap between international health recommendations and local implementation challenges.
This study serves as a critical test for parents and healthcare providers regarding the long-term protection of newborns against chronic liver disease. Families in the region may eventually see changes to routine vaccination schedules as the country moves toward a 2028 birth-dose policy.
The takeaway
Early vaccination remains the most effective intervention to prevent chronic infection and subsequent life-threatening complications like liver cancer. Understanding the impact of vaccination timing is vital for establishing health standards that protect infants globally.
Further reading
For more information on infant health and early immunization, visit the /lifestyle/family/babies/ section.
Live Poll
Should researchers use local standards of care for clinical trials in low-income countries?
